Hemoadsorption: consensus report of the 30th Acute Disease Quality Initiative workgroup
Rinaldo Bellomo,Ghada Ankawi,Sean M Bagshaw,Ian Baldwin,Rajit Basu,Gabriella Bottari,Vincenzo Cantaluppi,William Clark,Silvia De Rosa,Lui G Forni,Dana Fuhrman,Stuart Goldstein,Hernando Gomez,Faeq Husain-Syed,Michael Joannidis,Kianoush Kashani,Anna Lorenzin,Ravindra Mehta,Patrick T Murray,Ragi Murugan,Marlies Ostermann,Neesh Pannu,Vedran Premuzic,John Prowle,Thiago Reis,Thomas Rimmelé,Claudio Ronco,Mitch Rosner,Antoine Schneider,Emily See,Danielle Soranno,Gianluca Villa,Adam Whaley-Connell,Alexander Zarbock
DOI: https://doi.org/10.1093/ndt/gfae089
2024-11-27
Abstract:Adsorption-based extracorporeal therapies have been subject to technical developments and clinical application for close to five decades. More recently, new technological developments in membrane and sorbent manipulation have made it possible to deliver more biocompatible extracorporeal adsorption therapies to patients with a variety of conditions. There are several key rationales based on physicochemical principles and clinical considerations that justify the application and investigation of such therapies as evidenced by multiple ex vivo, experimental and clinical observations. Accordingly, unspecific adsorptive extracorporeal therapies have now been applied to the treatment of a wide array of conditions from poisoning to drug overdoses, to inflammatory states and sepsis, and acute or chronic liver and kidney failure. In response to the rapidly expanding knowledge base and increased clinical evidence, we convened an Acute Disease Quality Initiative consensus conference dedicated to such treatment. The data show that hemoadsorption has clinically acceptable short-term biocompatibility and safety, technical feasibility and experimental demonstration of specified target molecule removal. Pilot studies demonstrate potentially beneficial effects on physiology and larger studies of endotoxin-based hemoadsorption have identified possible target phenotypes for larger randomized controlled trials. Moreover, in a variety of endogenous and exogenous intoxications, removal of target molecules has been confirmed in vivo. However, some studies have raised concerns about harm, or failed to deliver benefits. Thus, despite many achievements, modern hemoadsorption remains a novel and experimental intervention with limited data, and a large research agenda.